149 related articles for article (PubMed ID: 38053080)
1. Prognostic factors for intermediate- or high-risk neuroblastomas in children in China.
Zhang Y; Zhang WL; Huang DS; Wang YZ; Hu HM; Zhi T; Mei YY
BMC Pediatr; 2023 Dec; 23(1):617. PubMed ID: 38053080
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
Berlanga P; Pasqualini C; Pötschger U; Sangüesa C; Castellani MR; Cañete A; Luksch R; Elliot M; Schreier G; Kropf M; Morgenstern D; Papadakis V; Ash S; Ruud E; Brock P; Wieczorek A; Kogner P; Trahair T; Ambros P; Boterberg T; Castel V; Valteau-Couanet D; Ladenstein R
Eur J Cancer; 2021 Feb; 144():1-8. PubMed ID: 33316634
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
5. Survival patterns of childhood neuroblastoma: an analysis of clinical data from Southern-Eastern European countries.
Karalexi MA; Servitzoglou M; Papadakis V; Kachanov D; Česen Mazič M; Baka M; Moschovi M; Kourti M; Polychronopoulou S; Stiakaki E; Hatzipantelis E; Dana H; Stefanaki K; Malama A; Themistocleous MS; Strantzia K; Shamanskaya T; Bouka P; Panagopoulou P; Kantzanou M; Ntzani E; Dessypris N; Petridou ET
Eur J Cancer Prev; 2023 May; 32(3):254-263. PubMed ID: 32925511
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
7. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
[TBL] [Abstract][Full Text] [Related]
8. A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis.
Kreitz K; Ernst A; Schmidt R; Simon T; Fischer M; Volland R; Hero B; Berthold F
Cancer Med; 2019 Dec; 8(17):7236-7243. PubMed ID: 31631570
[TBL] [Abstract][Full Text] [Related]
9. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Whittle SB; Smith V; Silverstein A; Parmeter M; Minard CG; Bernhardt MB; Zage PE; Venkatramani R; Nuchtern JG; Heczey A; Russell HV; Shohet JM; Foster JH
Pediatr Blood Cancer; 2020 Oct; 67(10):e28417. PubMed ID: 32729196
[TBL] [Abstract][Full Text] [Related]
10. [Occurrence and prognostic impact of selected factors in neuroblastoma in children].
Wieczorek A; Balwierz W
Przegl Lek; 2010; 67(6):393-8. PubMed ID: 21344768
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of
Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.
Basta NO; Halliday GC; Makin G; Birch J; Feltbower R; Bown N; Elliott M; Moreno L; Barone G; Pearson AD; James PW; Tweddle DA; McNally RJ
Br J Cancer; 2016 Oct; 115(9):1048-1057. PubMed ID: 27701387
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
15. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.
Henderson MJ; Haber M; Porro A; Munoz MA; Iraci N; Xue C; Murray J; Flemming CL; Smith J; Fletcher JI; Gherardi S; Kwek CK; Russell AJ; Valli E; London WB; Buxton AB; Ashton LJ; Sartorelli AC; Cohn SL; Schwab M; Marshall GM; Perini G; Norris MD
J Natl Cancer Inst; 2011 Aug; 103(16):1236-51. PubMed ID: 21799180
[TBL] [Abstract][Full Text] [Related]
16. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
17. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes among high-risk neuroblastoma patients receiving non-immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group.
Suwannaying K; Monsereenusorn C; Rujkijyanont P; Techavichit P; Phuakpet K; Pongphitcha P; Chainansamit SO; Chotsampancharoen T; Winaichatsak A; Traivaree C; Sathitsamitphong L; Kanjanapongkul S; Komvilaisak P; Sanpakit K; Photia A; Seksarn P; Wiangnon S; Hongeng S;
Pediatr Blood Cancer; 2022 Sep; 69(9):e29757. PubMed ID: 35560972
[TBL] [Abstract][Full Text] [Related]
19. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
[No Abstract] [Full Text] [Related]
20. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol.
Olgun N; Kansoy S; Aksoylar S; Cetingul N; Vergin C; Oniz H; Sarialioglu F; Kantar M; Uysal K; Tuncyurek M; Kargi A; Aktas S; Bayol U; Karaca I; Arikan A; Balik E; Aktug T; Elmas N; Kovanlikaya A; Kinay M; Anacak Y; Degirmenci B; Burak Z
Pediatr Hematol Oncol; 2003; 20(3):211-8. PubMed ID: 12637217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]